2017년 10월 30일 09:55

Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM™) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Celgene Corporation (NASDAQ:CELG) today announced detailed results from the phase III SUNBEAM™ trial evaluating the efficacy and safety of ozanimod, a novel, oral, selective sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, versu...

건강제약연구개발

2017년 10월 20일 09:55

Phase III Efficacy and Safety Data for Oral Ozanimod in Relapsing Multiple Sclerosis to Be Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Celgene Corporation (NASDAQ:CELG) today announced that new data on the efficacy and safety of ozanimod, a novel, oral, selective, sphingosine 1-phosphate 1 (S1PR1) and 5 (S1PR5) receptor modulator, in relapsing multiple sclerosis (RMS) were accept...

건강제약연구개발

2017년 10월 17일 10:10

Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease and Ulcerative Colitis to Be Presented at World Congress of Gastroenterology at ACG2017

Celgene Corporation (NASDAQ:CELG) today announced that phase 2 data of investigational compound ozanimod in Crohn’s disease and ulcerative colitis will be presented at the World Congress of Gastroenterology at ACG2017 (WCOG at ACG2017) in Orlando....

건강제약연구개발

2017년 6월 15일 11:25

Phase 2a Safety and Efficacy Data Support Further Development of Oral CC-220 in Patients with Lupus

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results from the phase 2a SLE-001 trial evaluating CC-220, the Company's investigational, oral immunomodulatory compound, at the Annual Eur...

건강제약연구개발

2017년 6월 8일 16:45

Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced new efficacy and safety data from the ongoing Phase 1 dose-escalation and expansion study evaluating investigational oral IDHIFA® (enasidenib) in patie...

건강제약연구개발

2017년 6월 8일 16:45

경구용 IDHIFA®(에나시데닙), IDH2변이가 있는 재발성 또는 난치성 급성 골수성 백혈병(AML) 환자를 대상으로 한 1상 임상시험의 업데이트 데이터 통해 완전 반응 및 반응 기간 개선 입증

세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)과 아기오스 제약(Agios Pharmaceuticals, Inc.)(나스닥: AGIO)이 동위구연산염 탈수소효소-2(IDH2)변이가 있는 재발성 또는 난치성 급성 골수성 백혈병(R/R AML) 환자를 대상으로 임상시험 단계에 있는 경구용...

건강제약연구개발

2017년 3월 6일 09:35

Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy

Celgene Corporation (NASDAQ:CELG) today announced that results from its phase 4 UNVEIL trial evaluating OTEZLA® (apremilast), the Company‘s oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate plaque psoriasis with a ...

건강제약연구개발

2017년 3월 6일 09:20

Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress

Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), conducted in patients with moderate or moderate to severe ...

건강제약연구개발

2016년 12월 21일 11:40

Oral PDE-4 Inhibitor, OTEZLA®, Approved for the Treatment of Plaque Psoriasis and Psoriatic Arthritis in Japan

Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA® (apremilast), Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan’s Ministry of Health, Labor and Welfare (MHLW) fo...

건강제약연구개발

2016년 12월 8일 19:25

ABOUND Data Presented at the World Conference on Lung Cancer Further Explores Safety and Efficacy of ABRAXANE® for Challenging Patient Populations

Celgene Corporation (NASDAQ:CELG) today announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-s...

건강제약연구개발

2016년 12월 8일 19:25

치료가 어려운 환자에 대해 아브락산의 안전성과 효능을 더 밝힌 ABOUND 임상 중간 결과, 세계폐암컨퍼런스(WCLC)서 발표

세엘진 코퍼레이션(Celgene Corporation, 이하 ‘세엘진’)(나스닥: CELG)이 오늘 아브락산(ABRAXANE®)(주사형 현탁액의 파클리탁셀 단백질 결합 입자, 알부민 결합)을 진행성 비소세포폐암(NSCLC) 환자에게 사용하여 효능을 평가한 ABOUND 임상시험의 중간 결과를 발...

건강제약연구개발

2016년 11월 15일 14:00

Data on Early Onset of Efficacy for Oral OTEZLA® (apremilast) in Active Psoriatic Arthritis Presented at American College of Rheumatology

Celgene Corporation (NASDAQ: CELG) today announced findings from the ACTIVE phase 3b clinical trial of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), at the 2016 American College of Rheumatology/Associ...

건강제약연구개발

2016년 10월 18일 14:05

Oral Ozanimod Efficacy and Safety Results from Phase 2 TOUCHSTONE Extension Trial in Patients with Ulcerative Colitis to Be Presented at UEGW and ACG

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe ulcerative...

건강제약연구개발

2016년 10월 17일 11:15

Oral GED-0301 Phase 1b Results Show Clinical Remission and Endoscopic Response at Week 12 in Patients with Active Crohn’s Disease

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the effects of investigational oral GED-0301...

건강제약연구개발

2016년 10월 14일 11:20

Celgene to Present New Data on Investigational Compounds at UEGW and ACG Congresses

Celgene Corporation (NASDAQ:CELG) today announced that findings from clinical trials of investigational compounds GED-0301 (mongersen), ozanimod and RPC4046 will be presented at the United European Gastroenterology (UEG) Week, October 15-19, in Vi...

건강제약연구개발

2016년 6월 8일 18:00

Data Presented at ASCO 2016 Builds upon Foundation of Abraxane® Plus Gemcitabine as a First-Line Treatment in Patients with Metastatic Pancreatic Cancer

Celgene Corporation (NASDAQ:CELG) today announced that results from multiple sponsored and independent studies presented during the 52nd ASCO Annual Meeting evaluated the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspensi...

건강제약연구개발

2016년 6월 8일 18:00

ASCO 2016, 전이성 췌장암 환자의 일차 치료로서 아브락산과 젬시타빈의 병행 치료 기반 마련

세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)이 오늘 제52회 미국임상종양학회(ASCO) 연례 학술대회에서 발표된 다수의 후원 및 독립 연구 결과가 전이성 췌장암 1차 치료에 젬시타빈(gemcitabine)과 아브락산(ABRAXANE®)(주사형 현탁액의 파클리탁셀 단백...

건강제약연구개발

2016년 6월 8일 17:20

Pooled Data from Meta-Analysis Suggest Significant Overall Survival Benefit of Investigational REVLIMID® Maintenance Following Autologous Stem Cell Transplant in Multiple Myeloma

Celgene Corporation (NASDAQ:CELG) today announced data from a meta-analysis of overall survival in multiple myeloma (MM) patients receiving investigational maintenance treatment with REVLIMID® (lenalidomide) capsules following high-dose melphalan ...

건강제약연구개발

2016년 6월 8일 17:20

메타분석 자료, 다발성 골수종에 자가 줄기세포 이식 뒤 임상시험 레블리미드 유지 요법에서 뚜렷한 전체 생존기간 증가 보고

세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)이 오늘 고용량 멜파란(melphalan)과 자가 줄기세포 이식(ASCT)에 이어 레블리미드(REVLIMID®: 성분명 레날리도마이드(lenalidomide)) 캡슐로 임상시험 유지 치료를 받은 다발성 골수종 (MM) 환자의 전체 생존...

건강제약연구개발

2016년 3월 21일 13:15

Oral Ozanimod Showed Histologic Improvements in Patients with Ulcerative Colitis in the Phase 2 TOUCHSTONE Trial

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that additional data of exploratory endpoints from the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with moderate to severe u...

건강제약연구개발

2016년 3월 8일 12:15

Oral OTEZLA® (Apremilast) Long-Term Safety Data Presented at American Academy of Dermatology Congress

Celgene Corporation (NASDAQ: CELG) today announced that long-term safety findings from ongoing clinical trials of OTEZLA® (apremilast), the Company‘s oral, selective inhibitor of phosphodiesterase 4 (PDE4), were presented at the American Academy o...

건강제약연구개발

2016년 3월 7일 10:05

Oral OTEZLA® (apremilast) Data from Open-Label Phase of ESTEEM and LIBERATE™ Trials to Be Presented at American Academy of Dermatology Congress

Celgene Corporation (NASDAQ:CELG) today announced that findings from ongoing clinical trials of OTEZLA® (apremilast), the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4), in patients with moderate to severe plaque psoriasis and p...

건강제약연구개발

2016년 2월 19일 14:10

Oral Ozanimod 72-Week Phase 2 Results From RADIANCE Trial in Relapsing Multiple Sclerosis Presented At ACTRIMS

Celgene Corporation (NASDAQ:CELG) today announced 72-week results from the RADIANCE phase 2 trial of ozanimod, an investigational selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis. The results were presented a...

건강제약연구개발

2015년 10월 27일 11:55

Phase 2 Maintenance Data from Oral Ozanimod TOUCHSTONE Study in Ulcerative Colitis Presented at UEG Week

Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today presented results from the maintenance phase of the TOUCHSTONE phase 2 clinical trial of Ozanimod, an investigational compound, in patients with mod...

건강제약연구개발

2015년 10월 27일 11:55

경구용 ‘오자니모드’의 궤양성 대장염 환자 대상 ‘TOUCHSTONE’ 2상 유지치료 시험 결과, 통합 유럽 위장병학(UEG) 주간 행사서 발표

세엘진 코퍼레이션(Celgene Corporation)(나스닥: CELG)의 완전 소유 자회사인 세엘진 인터내셔널(Celgene International Sàrl)이 오늘 스페인 바르셀로나에서 개최된 통합 유럽 위장병학 주간(United European Gastroenterology [UEG]Week) 행사에서 중등도~중증 궤...

건강제약연구개발